$0.51 EPS Expected for Customers Bancorp, Inc. (CUBI); Coherus Biosciences (CHRS) Sellers Increased By 0.88% Their Shorts

January 18, 2018 - By Darrin Black

Coherus Biosciences Incorporated (NASDAQ:CHRS) had an increase of 0.88% in short interest. CHRS’s SI was 5.96M shares in January as released by FINRA. Its up 0.88% from 5.90 million shares previously. With 667,800 avg volume, 9 days are for Coherus Biosciences Incorporated (NASDAQ:CHRS)’s short sellers to cover CHRS’s short positions. The SI to Coherus Biosciences Incorporated’s float is 15.51%. The stock decreased 4.17% or $0.525 during the last trading session, reaching $12.075. About 560,262 shares traded. Coherus Biosciences, Inc. (NASDAQ:CHRS) has risen 17.62% since January 18, 2017 and is uptrending. It has outperformed by 0.92% the S&P500.

Analysts expect Customers Bancorp, Inc. (NYSE:CUBI) to report $0.51 EPS on January, 25.They anticipate $0.25 EPS change or 32.89% from last quarter’s $0.76 EPS. CUBI’s profit would be $15.71 million giving it 14.60 P/E if the $0.51 EPS is correct. After having $0.61 EPS previously, Customers Bancorp, Inc.’s analysts see -16.39% EPS growth. The stock increased 0.07% or $0.02 during the last trading session, reaching $29.78. About 176,539 shares traded. Customers Bancorp, Inc. (NYSE:CUBI) has risen 10.83% since January 18, 2017 and is uptrending. It has underperformed by 5.87% the S&P500.

Among 6 analysts covering Customers Bancorp (NYSE:CUBI), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Customers Bancorp had 22 analyst reports since October 30, 2015 according to SRatingsIntel. As per Tuesday, September 20, the company rating was maintained by Keefe Bruyette & Woods. The stock of Customers Bancorp, Inc. (NYSE:CUBI) has “Outperform” rating given on Thursday, December 8 by FBR Capital. On Monday, December 19 the stock rating was maintained by Maxim Group with “Buy”. The rating was maintained by Maxim Group with “Buy” on Thursday, January 4. The firm earned “Buy” rating on Thursday, July 27 by Boenning & Scattergood. The stock of Customers Bancorp, Inc. (NYSE:CUBI) has “Hold” rating given on Thursday, June 29 by Keefe Bruyette & Woods. On Friday, October 20 the stock rating was maintained by Maxim Group with “Buy”. The firm has “Outperform” rating given on Friday, October 30 by FBR Capital. The rating was maintained by Keefe Bruyette & Woods on Tuesday, October 3 with “Hold”. The stock has “Buy” rating by Maxim Group on Thursday, October 26.

Customers Bancorp, Inc. operates as the bank holding firm for Customers Bank that provides financial services and products to small and middle market businesses, not-for-profits, and consumers. The company has market cap of $917.41 million. The firm accepts various deposit products, such as checking, savings, money market deposit, time deposit, individual retirement, and non-retail time deposit accounts, as well as certificates of deposit. It has a 15.41 P/E ratio. The Company’s loan products include commercial lending products comprising business banking commercial and industrial lending; small and middle market business banking, such as small business administration loans; multi-family and commercial real estate lending; and commercial loans to mortgage originators, as well as consumer lending products comprising mortgage and home equity lending.

Investors sentiment decreased to 1.18 in Q3 2017. Its down 0.45, from 1.63 in 2017Q2. It is negative, as 15 investors sold Customers Bancorp, Inc. shares while 53 reduced holdings. 24 funds opened positions while 56 raised stakes. 25.90 million shares or 0.33% more from 25.81 million shares in 2017Q2 were reported. Comerica Bancorporation has 0.01% invested in Customers Bancorp, Inc. (NYSE:CUBI). Eagle Boston Invest Mgmt Inc owns 363,984 shares or 1.23% of their US portfolio. Millennium Limited invested in 338,716 shares or 0.02% of the stock. Intll Gp reported 0% stake. Moreover, Wasatch Advisors has 0.21% invested in Customers Bancorp, Inc. (NYSE:CUBI) for 466,392 shares. Retail Bank Of Montreal Can holds 109,499 shares or 0% of its portfolio. Boston Advsr holds 0.16% in Customers Bancorp, Inc. (NYSE:CUBI) or 213,100 shares. Royal Bancorp Of Canada has 2,476 shares for 0% of their portfolio. Piedmont Advisors holds 6,273 shares or 0% of its portfolio. 3,300 are owned by Evercore Wealth Management Ltd Limited Liability Company. Qs Limited Liability reported 0.03% stake. Tieton Capital Management Limited Liability Com holds 4.83% or 172,135 shares. Cornerstone Mngmt Ltd Llc holds 0.04% or 173,434 shares. Citadel Advsr Limited Liability Company accumulated 0% or 9,210 shares. Moreover, Whittier has 0% invested in Customers Bancorp, Inc. (NYSE:CUBI).

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 1.02, from 2.09 in 2017Q2. It dived, as 21 investors sold Coherus Biosciences, Inc. shares while 23 reduced holdings. 9 funds opened positions while 38 raised stakes. 46.59 million shares or 17.08% more from 39.79 million shares in 2017Q2 were reported. Kohlberg Kravis Roberts And Lp reported 0.47% in Coherus Biosciences, Inc. (NASDAQ:CHRS). Highbridge Capital Mngmt Ltd Liability Corporation has 33,906 shares for 0.01% of their portfolio. Proshare Advsrs Ltd Liability Corp invested 0% in Coherus Biosciences, Inc. (NASDAQ:CHRS). Rhenman And Prtn Asset stated it has 0.31% in Coherus Biosciences, Inc. (NASDAQ:CHRS). Parallax Volatility Advisers Limited Partnership holds 0% in Coherus Biosciences, Inc. (NASDAQ:CHRS) or 1,021 shares. Credit Suisse Ag reported 142,482 shares. Brown Advisory accumulated 594,021 shares. Alyeska Inv Gp Inc Limited Partnership reported 559,581 shares stake. D E Shaw And stated it has 107,021 shares or 0% of all its holdings. Tiaa Cref Invest Mgmt Limited Company accumulated 0.01% or 1.03M shares. Schwab Charles Invest Mgmt has 157,681 shares. Comml Bank Of America De reported 28,626 shares. Guggenheim Limited Liability Corporation holds 0% or 16,980 shares. C Gp Hldg A S, Denmark-based fund reported 238,971 shares. Geode Capital Mngmt Ltd Llc holds 379,392 shares or 0% of its portfolio.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $709.06 million. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com